子宮内膜症治療薬の世界市場:市場インサイト、疫学分析、市場予測

◆英語タイトル:Endometriosis - Market Insights, Epidemiology and Market Forecast-2023
◆商品コード:DLVE704021
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2017年3月
◆ページ数:85
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2営業日以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名使用)USD4,950 ⇒換算¥534,600見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD9,900 ⇒換算¥1,069,200見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD14,850 ⇒換算¥1,603,800見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

DelveInsight’s “Endometriosis – Market Insights, Epidemiology and Market Forecast-2023”Report provides an overview of the disease and global market size of the Endometriosis for the
7MM (United States, EU5 (France, Germany, Italy, Spain and UK) and Japan. It also includes
global historical and forecasted epidemiological data for the prevalent, diagnosed and treatable
cases of Endometriosis from 2013-2023.
Endometriosis is the abnormal growth of endometrial tissue similar to that which lines the
interior of the uterus, but in a location outside of the uterus. It is usually developed in
Peritoneum, fallopian tubes, Ovaries, Cul-de-sac (the space behind the uterus), Outer surfaces
of the uterus, bladder, ureters, intestines, and rectum.
Worldwide in 2012, 527,600 women were diagnosed with Endometriosis. The mortality rate
was 1.7 to 2.4 per 100,000 women. In the United States, as with other developed countries
Endometriosis was the most common gynecologic malignancy, with over 60,000 new cases and
over 10,000 deaths from the disease in each year.
Lupron, developed by Abbvie is the top selling drug of Endometriosis contributing to majority of
the market size. Other top players include Visanne/Dienogest (Bayer Healthcare), Zoladex
(AstraZeneca), Synarel (Pfizer) and Depo-SubQ Provera (Pfizer). According to DelveInsight, the
worldwide Endometriosis market is estimated to be USD 1.91 Billion by 2023 at a CAGR of
1.33%.
The report is built using data and information sourced from proprietary databases, primary and
secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope
- Report covers the disease overview including pathophysiology, symptoms, diagnosis,
disease management, and current treatment options.
- Marketed information including available prescription drugs, its patent and exclusivity
details.
- The Report also covers the detailed global historical and forecasted epidemiological data
covering United States, EU5 and Japan from 2013-2023.
- It also provides Market size of Endometriosis for United States, EU5 and Japan from
2013 and forecasted Market size to 2023.

【レポートの目次】

Report Introduction
Endometriosis Market Overview at a Glance
Global Market Size of Endometriosis in 2015
Global Market Size of Endometriosis in 2023
Endometriosis
• Overview
• Stages
• Types
• Pathophysiology
• Risk Factors
• Diagnosis
• Treatment
Epidemiology of Endometriosis in 7MM
• United States
• EU5
• United Kingdom
• Germany
• France
• Italy
• Spain
• Japan
Treatment Algorithm
Initial Treatment
Treatment of Recurrent Endometriosis
Add-Back Therapy
Current Unmet Needs
Marketed Drugs
Lupron
Description
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Depo-SubQ Provera 104
Description
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Visanne
Description
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Zoladex
Description
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Synarel
Description
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Pamorelin/Decapeptyl/Trelstar
Description
Regulatory Milestones
Advantages and Disadvantages
Product Profile
Emerging Therapies
Elagolix: AbbVie Inc
Description
Regulatory Milestones
Clinical Development
Product Profile
Clinical Trial by Phase
Safety and Efficacy
Femitra: EndoCeutics Inc
Description
Product Profile
BAY 86-5300: Bayer HealthCare Pharmaceuticals
Description
Clinical Development
Product Profile
Clinical Trial by Phase
Global Endometriosis: Country-Wise Market Analysis
Total Market Size of Endometriosis (2013-2023)
• United States
• EU5
• United Kingdom
• Germany
• France
• Italy
• Spain
• Japan
Market Drivers
Market Barriers
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight

Table 1: Prevalent, Diagnosed and Treatable cases of Endometriosis in United States (2013-2023)
Table 2: Prevalent, Diagnosed and Treatable cases of Endometriosis in United Kingdom (2013-2023)
Table 3: Prevalent, Diagnosed and Treatable cases of Endometriosis in Germany (2013-2023)
Table 4: Prevalent, Diagnosed and Treatable cases of Endometriosis in France (2013-2023)
Table 5: Prevalent, Diagnosed and Treatable cases of Endometriosis in Italy (2013-2023)
Table 6: Prevalent, Diagnosed and Treatable cases of Endometriosis in Spain (2013-2023)
Table 7: Prevalent, Diagnosed and Treatable cases of Endometriosis in Japan (2013-2023)
Table 8: Total Market size of Endometriosis in USD Billion (2013-2023)
Table 9: United States Market Size of Endometriosis in USD, Billion (2013-2023)
Table 10: United Kingdom Market Size of Endometriosis in USD, Billion (2013-2023)
Table 11: Germany Market Size of Endometriosis in USD, Billion (2013-2023)
Table 12: France Market Size of Endometriosis in USD, Billion (2013-2023)
Table 13: Italy Market Size of Endometriosis in USD, Billion (2013-2023)
Table 14: Spain Market Size of Endometriosis in USD, Billion (2013-2023)
Table 15:Japan Market Size of Endometriosis in USD, Billion (2013-2023)


Figure 1: Pathogenesis and Pathophysiology of Endometriosis
Figure 2: Risk Factors associated with Endometriosis
Figure 3: Treatment for endometriosis
Figure 4: Prevalent Population of Endometriosis in United States (2013-2023)
Figure 5: Prevalent, Diagnosed and Treatable cases of Endometriosis in United States (2013-2023)
Figure 6: Prevalent Population of Endometriosis in United Kingdom (2013-2023)
Figure 7: Prevalent, Diagnosed and Treatable cases of Endometriosis in United Kingdom (2013-2023)
Figure 8: Prevalent Population of Endometriosis in Germany (2013-2023)
Figure 9: Prevalent, Diagnosed and Treatable cases of Endometriosis in Germany (2013-2023)
Figure 10: Prevalent Population of Endometriosis in France (2013-2023)
Figure 11: Prevalent, Diagnosed and Treatable cases of Endometriosis in France (2013-2023)
Figure 12: Prevalent Population of Endometriosis in Italy (2013-2023)
Figure 13: Prevalent, Diagnosed and Treatable cases of Endometriosis in Italy (2013-2023)
Figure 14: Prevalent Population of Endometriosis in Spain (2013-2023)
Figure 15: Prevalent, Diagnosed and Treatable cases of Endometriosis in Spain (2013-2023)
Figure 16: Prevalent Population of Endometriosis in Japan (2013-2023)
Figure 17: Prevalent, Diagnosed and Treatable cases of Endometriosis in Japan (2013-2023)
Figure 18: Treatment Algorithm, 2017
Figure 19: Current Unmet Needs of Endometriosis
Figure 20: Total Market Size of Endometriosis in USD, Billion (2013-2023)
Figure 21: United States Market Size of Endometriosis in USD, Billion (2013-2023)
Figure 22: United Kingdom Market Size of Endometriosis in USD, Billion (2013-2023)
Figure 23: Germany Market Size of Endometriosis in USD, Billion (2013-2023)
Figure 24: France Market Size of Endometriosis in USD, Billion (2013-2023)
Figure 25: Italy Market Size of Endometriosis in USD, Billion (2013-2023)
Figure 26: Spain Market Size of Endometriosis in USD, Billion (2013-2023)
Figure 27:Japan Market Size of Endometriosis in USD, Billion (2013-2023)

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 子宮内膜症治療薬の世界市場:市場インサイト、疫学分析、市場予測(Endometriosis - Market Insights, Epidemiology and Market Forecast-2023)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆